Clinical chemistry analyzers market seen reaching $22.64 billion by 2030

The Business Research Company says the clinical chemistry analyzers market is projected to grow from $15.49 billion in 2025 to $22.64 billion by 2030, driven by rising diagnostic demand, chronic disease prevalence and automation in labs. North America held the largest share in 2025, while demand is expected to broaden as health systems adopt faster, more connected testing.

Why it matters: - Clinical chemistry analyzers support diagnosis and monitoring for infectious and chronic diseases by measuring compounds in serum, plasma and urine. - Demand for faster, more precise testing is pushing hospitals and laboratories toward automation, point-of-care testing and connected diagnostic systems. - The market outlook signals continued investment in lab infrastructure, smart laboratory tools and analytics that can improve workflow and patient care.

What happened: - The Business Research Company published its Clinical Chemistry Analyzers Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report estimates the market will rise from $15.49 billion in 2025 to $16.63 billion in 2026. - The report projects the market will reach $22.64 billion by 2030, implying an 8.0% CAGR over the forecast period. - North America held the largest market share in 2025. - The report includes regional coverage for Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, and the Middle East and Africa. - A free sample of the report is available. - The full market report is available online.

The details: - Clinical chemistry analyzers are used in medical laboratories to measure metabolites, electrolytes, proteins and pharmaceuticals in biological fluids. - The report says historical growth was supported by higher diagnostic test volumes, growth in hospital laboratory infrastructure, rising chronic disease prevalence, broad adoption of automated lab equipment and steady availability of standardized reagents. - The report says future growth will be driven by demand for rapid diagnostic solutions, decentralized testing models, smart laboratory technology investment, personalized medicine and advanced analytics in clinical diagnostics. - Key trends identified in the report include fully automated analyzers, AI-based diagnostic support systems, high-throughput testing devices, point-of-care chemistry testing and stronger data connectivity with laboratory information systems. - The report highlights increased infectious and chronic disease burden as a major catalyst for analyzer demand. - The report cites a September 2023 UK Health Security Agency update showing tuberculosis cases in England rose 7% in the first half of 2023 versus the same period in 2022. - The 2026 edition of the report adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The forecast points to a market moving from routine lab testing toward more automated and data-driven workflows. - AI support and LIS integration suggest analyzers are becoming part of broader digital lab ecosystems, not just standalone instruments. - The emphasis on decentralized and point-of-care testing reflects pressure to bring diagnostics closer to patients and speed up clinical decisions.

What's next: - The market is expected to keep expanding through 2030 as laboratories adopt higher-throughput and more connected systems. - Ongoing disease burden and modernization of healthcare infrastructure are likely to sustain demand for analyzer capacity and test automation. - The report signals that vendors may compete more on software, connectivity and workflow integration as much as on instrument performance.

The bottom line: - Clinical chemistry analyzers remain a core diagnostics category, and the next phase of growth appears tied to automation, speed and digital integration.